London
· Delayed Price · Currency is GBP · Price in USD Anavex Life Sciences Company Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.
Anavex Life Sciences Corp.was incorporated in 2004 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2001 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Christopher Missling |
Contact Details
Address: 630 5th Avenue New York, Nevada 10111 United States | |
| Phone | 844 689 3939 |
| Website | anavex.com |
Stock Details
| Ticker Symbol | 0HFR |
| Exchange | London Stock Exchange |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US0327973006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Sandra Boenisch CPA, CGA | Principal Financial Officer and Treasurer |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer |
| Clint Tomlinson | Vice President of Corporate |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Dr. Kun Jin Ph.D. | Head of Biostatistics |
| David Goldberger R.Ph. | Senior Vice President of Regulatory Affairs |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior Vice President and Head of Research and Development |